Two months after its treatment for Duchenne-related cardiomyopathy was rejected, the company aligned with the agency on a ...

Decades of slow-moving research, along with broader failures of the healthcare system, have left millions of people in daily ...

New study data showed treatment slowed signs of disease progression by 75% after three years, a finding that could have ...

The trial failure removes from development a treatment Acadia acquired in a 2022 buyout and that was seen as a potential ...

After reviewing existing published literature, the agency initiated the approval of Wellcovorin — which GSK stopped selling ...

A deal with Dutch startup VarmX gives CSL an option to buy a Phase 3-ready drug that could reverse the effects of popular ...

Susan Monarez told Senators at a hearing Wednesday that Robert F. Kennedy Jr. pushed her out for refusing to rubber-stamp ...

Unified data also improves AI outputs. For example, by drawing up-to-date information from a variety of an organization’s ...

The British drugmaker’s commitment comes as some of its pharma peers question their U.K. presence amid a widening row there ...

The deal ends a short run as a publicly traded company for Metsera, which is being sold for more than double its IPO price ...

The drug, iberdomide, is one of a few protein-degrading medicines the company hopes to become successors to its blockbuster ...

The collapse in value of many biotechs over the past few years has created an opportunity for specialists like Xoma to “do ...